{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:13:53Z","timestamp":1791090833075,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Chemical Biology"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.cbpa.2010.03.023","type":"journal-article","created":{"date-parts":[[2010,4,18]],"date-time":"2010-04-18T11:01:36Z","timestamp":1271588496000},"page":"447-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["New antileishmanial candidates and lead compounds"],"prefix":"10.1016","volume":"14","author":[{"given":"Julian V","family":"Richard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl A","family":"Werbovetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbpa.2010.03.023_bib1","unstructured":"Leishmaniasis - magnitude of the problem on World Wide Web URL: http:\/\/www.who.int\/leishmaniasis\/burden\/magnitude\/burden_magnitude\/en\/index.html."},{"key":"10.1016\/j.cbpa.2010.03.023_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-3156.2008.02195.x","article-title":"Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India","volume":"14","author":"Olliaro","year":"2009","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.cbpa.2010.03.023_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/138955706775475993","article-title":"Development of miltefosine for the leishmaniases","volume":"6","author":"Berman","year":"2006","journal-title":"Minirev Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/AAC.01233-08","article-title":"In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity","volume":"53","author":"Kumar","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2010.03.023_bib6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1086\/605438","article-title":"Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment","volume":"49","author":"Sundar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2010.03.023_bib7","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1371\/journal.pntd.0000432","article-title":"WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study","volume":"3","author":"Ben Salah","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cbpa.2010.03.023_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.cbpa.2010.03.023_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MJT.0b013e3181822e90","article-title":"Current treatment for cutaneous leishmaniasis: a review","volume":"16","author":"Palumbo","year":"2009","journal-title":"Am J Therapeutics"},{"key":"10.1016\/j.cbpa.2010.03.023_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/092986709787458489","article-title":"Leishmaniasis: current treatment and prospects for new drugs and vaccines","volume":"16","author":"Kedzierski","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib11","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1021\/jm9004835","article-title":"Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania","volume":"52","author":"Cavalli","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib12","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1128\/AAC.00548-09","article-title":"In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences","volume":"53","author":"Vermeersch","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1021\/jm701166b","article-title":"Design and synthesis of potent antileishmanial cycloalkylidene-substituted ether phospholipid derivatives","volume":"51","author":"Calogeropoulou","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib14","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1016\/j.bmcl.2008.07.022","article-title":"Parallel synthesis and antileishmanial activity of ether-linked phospholipids","volume":"18","author":"Coghi","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2010.03.023_bib15","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1128\/AAC.01215-08","article-title":"Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana","volume":"53","author":"Serrano-Mart\u00edn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib16_1","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1128\/AAC.00505-09","article-title":"Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis","volume":"53","author":"Serrano-Mart\u00edn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0378-5173(02)00686-5","article-title":"Formulation of amphotericin B as nanosuspension for oral administration","volume":"254","author":"Kayser","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.cbpa.2010.03.023_bib18_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/600105","article-title":"Highly effective oral amphotericin B formulation against murine visceral leishmaniasis","volume":"200","author":"Wasan","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cbpa.2010.03.023_bib19","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejmech.2009.10.022","article-title":"Synthesis and antiprotozoal activity of 4-arylcoumarins","volume":"45","author":"Pierson","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bmcl.2007.10.091","article-title":"Azaterphenyl diamidines as antileishmanial agents","volume":"18","author":"Hu","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2010.03.023_bib21_1","doi-asserted-by":"crossref","unstructured":"Wang M, Zhu X, Srivastava A, Liu Q, Sweat J, Pandharkar T, Stephens C, Riccio E, Mandal S, Madhubala R, et al.: Novel arylimidamides for the treatment of visceral leishmaniasis. Antimicrob Agents Chemother (in press), doi:10.1128\/AAC.00250-10","DOI":"10.1128\/AAC.00250-10"},{"key":"10.1016\/j.cbpa.2010.03.023_bib22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/AAC.46.3.929-931.2002","article-title":"In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii","volume":"46","author":"Yardley","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib23","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1016\/j.bmc.2008.08.024","article-title":"Synthesis and biological evaluation of indolyl bisphosphonates as anti-bone resorptive and anti-leishmanial agents","volume":"16","author":"Singh","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib24","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/AAC.38.6.1339","article-title":"Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani","volume":"38","author":"Chen","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib25","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ejmech.2007.12.014","article-title":"Chemotherapy of leishmaniasis part VIII: synthesis and bioevaluation of novel chalcones","volume":"43","author":"Suryawanshi","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/jm7012166","article-title":"2-(3-Aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype","volume":"51","author":"Rechwald","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1128\/AAC.00522-07","article-title":"Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis","volume":"52","author":"Palit","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib28_1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.ejmech.2007.11.007","article-title":"Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies","volume":"43","author":"Roldos","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib29","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1128\/AAC.00124-08","article-title":"Activity of hydroxyurea against Leishmania mexicana","volume":"52","author":"Martinez-Rojano","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.bmc.2008.12.003","article-title":"Ivermectin-derived leishmanicidal compounds","volume":"17","author":"dos Santos","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib31","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bmc.2008.11.031","article-title":"Redox-active dinitrophenylthioethers against Leishmania: synthesis, structure\u2013activity relationships and mechanism of action studies","volume":"17","author":"Delf\u00edn","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1126\/science.2392684","article-title":"Inhibition of Leishmanias but not host macrophages by the antitubulin herbicide trifluralin","volume":"249","author":"Chan","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.cbpa.2010.03.023_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bmc.2009.10.059","article-title":"Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents","volume":"18","author":"Esteves","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib34","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1016\/j.bmc.2008.02.052","article-title":"Synthesis and in vitro anti-leishmanial activity of 1-[5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-yl]- and 1-[5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl]-4-aroylpiperazines","volume":"16","author":"Behrouzi-Fardmoghadam","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib35","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.ejmech.2008.03.039","article-title":"Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evaluation","volume":"44","author":"Poorajab","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib36","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01319-08","article-title":"Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB\/c mice","volume":"53","author":"Jaafari","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib37_1","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.bmcl.2009.03.039","article-title":"Peganine hydrochloride dihydrate an orally active antileishmanial agent","volume":"19","author":"Khaliq","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2010.03.023_bib38","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1128\/AAC.01146-09","article-title":"The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells","volume":"53","author":"Mendez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib39","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ejmech.2009.01.016","article-title":"Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines","volume":"44","author":"Sunduru","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib40","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1016\/j.bmcl.2009.07.081","article-title":"Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents","volume":"19","author":"Agarwal","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2010.03.023_bib41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1021\/jm00183a004","article-title":"Analogues of 8-[[6-diethylamino)hexyl]amino]-6-methoxy-4-methylquinoline as candidate antileishmanial agents","volume":"23","author":"LaMontagne","year":"1980","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib42","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/clinids\/19.6.1034","article-title":"Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis","volume":"19","author":"Sherwood","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cbpa.2010.03.023_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","article-title":"A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India","volume":"73","author":"Jha","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cbpa.2010.03.023_bib44_1","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/AAC.00645-07","article-title":"Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate","volume":"52","author":"Nanayakkara","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib45","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1016\/j.ejmech.2009.09.012","article-title":"A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity","volume":"44","author":"Guglielmo","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2007.03.003","article-title":"Synthesis and antiprotozoal activities of simplified analogs of naphthylisoquinoline alkaloids","volume":"43","author":"Bringmann","year":"2008","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib47","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1021\/jm801084u","article-title":"Structure\u2013activity relationship and studies on the molecular mechanism of leishmanicidal N,C-coupled arylisoquinolinium salts","volume":"52","author":"Ponte-Sucre","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib48_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejmech.2008.04.014","article-title":"Phase transfer catalyzed synthesis of bis-quinolines: antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation","volume":"44","author":"Palit","year":"2009","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib49_1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/jm9013086","article-title":"Fluorinated rhodacyanine (SJL-01) possessing high efficacy for visceral leishmaniasis (VL)","volume":"53","author":"Yang","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.cbpa.2010.03.023_bib50_1","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1128\/AAC.01616-07","article-title":"In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects","volume":"52","author":"Fernandes Rodrigues","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cbpa.2010.03.023_bib51","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.bmcl.2008.11.094","article-title":"Aryloxy cyclohexyl imidazoles: a novel class of antileishmanial agents","volume":"19","author":"Srinivas","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2010.03.023_bib52","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bmcl.2009.10.117","article-title":"Synthesis of substituted aryloxy alkyl and aryloxy aryl alkyl imidazoles as antileishmanial agents","volume":"20","author":"Bhandari","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbpa.2010.03.023_bib53","series-title":"Handbook of Animal Models of Infection: Experimental Models in Antimicrobial Chemotherapy","article-title":"Animal models of visceral leishmaniasis","author":"Croft","year":"1999"},{"key":"10.1016\/j.cbpa.2010.03.023_bib54","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","article-title":"The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response","volume":"166","author":"Melby","year":"2001","journal-title":"J Immunol"}],"container-title":["Current Opinion in Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593110000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1367593110000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T02:24:14Z","timestamp":1761272654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1367593110000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S1367593110000499"],"URL":"https:\/\/doi.org\/10.1016\/j.cbpa.2010.03.023","relation":{},"ISSN":["1367-5931"],"issn-type":[{"value":"1367-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New antileishmanial candidates and lead compounds","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbpa.2010.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}